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Abstract Merkel cell polyomavirus (MCPyV or MCV) is
the ﬁrst polyomavirus to be clearly implicated as a causal
agent underlying a human cancer, Merkel cell carcinoma
(MCC). Infection with MCPyV is common in the general
population, and a majority of adults shed MCPyV from the
surface of their skin. In this study, we quantitated MCPyV
DNA in skin swab specimens from healthy volunteers
sampled at different anatomical sites over time periods
ranging from 3 months to 4 years. The volunteers were
also tested using a serological assay that detects antibodies
speciﬁc for the MCPyV virion. There was a positive cor-
relation between MCPyV virion-speciﬁc antibody titers
and viral load at all anatomical sites tested (dorsal portion
of the hands, forehead, and buttocks) (Spearman’s r 0.644,
P\0.0001). The study results are consistent with previous
ﬁndings suggesting that the skin is primary site of chronic
MCPyV infection in healthy adults and suggest that the
magnitude of an individual’s seroresponsiveness against
the MCPyV virion generally reﬂects the overall MCPyV
DNA load across wide areas of the skin. In light of pre-
vious reports indicating a correlation between MCC and
strong MCPyV-speciﬁc seroresponsiveness, this model
suggests that poorly controlled chronic MCPyV infection
might be a risk factor in the development of MCC.
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Introduction
Merkel cell polyomavirus (MCPyV or MCV) is a newly
identiﬁed member of the viral family Polyomaviridae.I ti s
a small, non-enveloped, double-stranded DNA virus.
MCPyV was originally detected in Merkel cell carcinoma
(MCC) [1], a rare but highly lethal form of skin cancer.
MCPyV infection is thought to be very common among
healthy subjects, with an overall seroprevalence of 42–88%
[2–5].
More extensively studied human polyomaviruses, such
as BKPyV and JCPyV (also known as BKV and JCV), also
have a high seroprevalence in healthy human adults. Both
BKPyV and JCPyV can persist in the stratiﬁed epithelium
of the lower urinary tract, and periodic reactivation of the
infection can result in urinary shedding of virions [6–8].
Viral shedding increases with age, and the incidence of
viruria among elderly individuals can reach 70% for
JCPyV and 44% for BKPyV [9–12]. The similar age-
related increase in MCPyV seroprevalence among healthy
adults [2, 5] along with its presence in diverse anatomical
surfaces such as the skin, aerodigestive, and genitourinary
tracts [13–15] suggests that MCPyV may, like BKPyV and
JCPyV, often establish a persistent infection in stratiﬁed
epithelial tissues of healthy adults.
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DOI 10.1007/s00430-011-0200-7Although seroresponsiveness to the MCPyV VP1 capsid
protein is common among healthy adults, MCC patients
tend to show unusually strong seroresponses against the
viral capsid [2–4]. We have previously speculated that the
strong MCPyV-speciﬁc seroresponsiveness of MCC
patients might reﬂect a period of unusually high MCPyV
viral load in these patients. A direct correlation between
viral load and antigen-speciﬁc antibody titers has been
inferred for BKPyV and JCPyV infections [16–18] and in
several other viral infections, including Epstein-Barr virus
[19] human T-lymphotropic virus type-I [20] and inﬂuenza
virus H1N1 [21]. However, in other types of viral infec-
tions, there is an inverse correlation between viral load and
neutralizing antibody titers, e.g., Crimean-Congo hemor-
rhagic fever virus [22] and hepatitis C virus [23]. Thus, the
proposed correlation between individual subjects’ MCPyV
viral burden and MCPyV-speciﬁc antibody titers remains
speculative. In this study, serum samples and surface swab
specimens from the foreheads, hands and buttocks of
healthy volunteers were assayed quantitatively, with the
primary goal of determining whether there is a correlation
between the magnitude of individual subjects’ MCPyV
DNA load and MCPyV-speciﬁc seroresponsiveness.
Materials and methods
Volunteers and samples
Forty-seven healthy adults were invited to participate in the
study as volunteers. Subject ages ranged from 24 to
79 years (mean 44.7, median 42). Thirty-one participants
were women, and 16 were men. Informed consent was
obtained from each participant. Additionally, serum from
an 8-year-old male from whom skin swabs were available
from a previous study (24) was included (ID-A9); the latter
serum was obtained as a byproduct of samples drawn to
obtain serum titers after routine vaccinations. Both parents
consented to its use in this study. The study protocol was
approved by the ethics review board of the University of
Cologne, and the study was conducted according to the
Declaration of Helsinki principles. There were two cohorts
of volunteers, one with 16 volunteers (cohort A) and one
with 33 volunteers (cohort B). Cohort A was a subset of
volunteers described in a previous report [24]. One female
volunteer participated in both cohorts (number 14 in cohort
A is the same individual as number 29 in cohort B), but
independent swabs and sera were collected for the studies.
In cohort A, each participant had been requested to self-
swab three anatomical sites: (1) forehead (2) the dorsal
surface of the hand, and (3) the buttocks. Volunteers per-
formed 1–10 swabs at each site over a period of up to
4 years (24). For cohort B, one of the authors swabbed the
foreheads and hands of volunteers. For each cohort B
volunteer, swabbing was performed at 4 different time
points that spanned an interval of 3–5 months (mean 3.6),
with each swab being separated from the previous one by
15–74 days (mean 44). Volunteers from both cohorts
donated one or two serum samples. In instances where two
samples were available, they were collected 11–15 months
apart. Serum samples were heat inactivated at 56C for
30 min and stored at 4C until assayed.
Determination of viral load
DNA was extracted from the swabs as previously described
[24] using a QIAamp DNA mini kit (Qiagen, Germany), as
directed by the manufacturer. Quantitative real-time PCR
(qPCR) was performed as described by Sihto and col-
leagues [25], except that the elongation time was reduced
to 5 s using a LightCycler 480 Real-Time PCR system
(Roche). Beta-globin was used to normalize the samples
using Roche’s Light Cycler Control Kit DNA. The viral
load is expressed as the number of MCPyV DNA copies
divided by the number of beta-globin gene copies in 5 llo f
extracted DNA, respectively. The limit of detection of the
assay was deﬁned as 0.002 (i.e., 1 copy of MCPyV DNA
per 500 copies of beta-globin). When beta-globin was
detectable, swabs contained between 20 and 186,920
(mean 3,763, median 580) copies of beta-globin in 100 ll
of total extracted DNA. Samples in which MCPyV DNA
was not quantitatively detected were arbitrarily assigned a
value of 0.001 for graphical display.
Quantitation of MCPyV capsid-speciﬁc antibodies
Serum was analyzed for the presence of MCPyV-speciﬁc
neutralizing antibodies using a reporter vector-based assay
that has been previously described [3]. Detailed protocols
for reporter vector production and neutralization assay
methods are available at (http://home.ccr.cancer.gov/LCO).
Brieﬂy, MCPyV-based reporter vectors (pseudovirions)
were produced by transfecting 293TT cells [26] with plas-
mids pwM and ph2 m, expressing codon modiﬁed MCPyV
VP1 and VP2 structural genes, along with the reporter
plasmid phGluc. Plasmids used to produce viral stocks are
available from Addgene (http://www.addgene.org). Viral
stocks were puriﬁed from the lysates of transfected cells by
ultracentrifugation through iodixanol (Optiprep, Sigma)
gradients. Heat-inactivated sera were diluted 1:100 and
subjected to four-fold serial dilution. The diluted sera were
mixed with reporter vector stock for 1 h at 4C and used for
transduction of 293TT cells that were seeded at 30,000 cells
per well in 96-well plates. The assay used a reporter vector
dose of 80 pg of VP1 per well. After 72 h, conditioned
culture supernatants were assayed for luciferase activity
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by the manufacturer. Prism software (Graphpad) was used
to calculate the 50% neutralizing dilution (EC50) and the
95% conﬁdence interval for each serum sample.
Statistical analysis
Prism software (Graphpad) was used for all analyses. We
determined whether data were normally distributed using
D’Agostino & Pearson omnibus K-squared test. Because
neither the MCPyV DNA load data sets nor the MCPyV-
neutralizing titer data sets displayed a normal Gaussian
distribution, it was necessary to use a non-parametric test
to determine correlations. Two-tailed Spearman rank cor-
relation coefﬁcients were obtained, along with the associ-
ated P value.
Results
MCPyV viral load in skin from healthy volunteers
The presence of MCPyV DNA and virions on the skin of
healthy volunteers has been demonstrated in several studies
[13–15, 27]. The high frequency at which the virus is found
in the general population suggests that colonization/infec-
tion by the virus is probably both ubiquitous and chronic.
In this study, swab specimens from two or three skin sites
were tested for MCPyV DNA content by quantitative real-
time PCR (qPCR), with the goal of determining whether
the amount of MCPyV shed from the various sites was
similar or different for a given individual. Subjects were
sampled at various time points to determine whether the
MCPyV DNA load remains constant through time.
Sixteen volunteers (cohort A) self-sampled at three skin
sites: the back of the hand, the forehead, and the buttocks.
A separate set of 33 volunteers (cohort B) were sampled at
two skin sites (back of the hand and forehead). For each
sample, the number of copies of MCPyV DNA was stan-
dardized to the number of copies of human beta-globin
DNA. The MCPyV DNA load at a given anatomic site for a
given individual showed no consistent trends over time.
Some individuals (A12, B9, B23, B25, etc., Supplemental
Table 1) showed remarkably stable loads in all anatomical
sites over time, with data points differing by less than one
log. In other individuals (B8, B16, B24, etc.), the MCPyV
DNA levels at some anatomic sites were lower for the
initial swab, then they increased by two or three logs at the
second and/or third time point, only to come back to
baseline levels by the end of the study (data not shown and
Supplemental Table 1). Conversely, some individuals (A7,
A9, B15, etc.) initially had a higher MCPyV load at one or
more anatomic sites, followed by one or more swabs that
declined by up to two logs, followed by swabs that were
less than one log from the original sample. While a dif-
ference of two logs might seem large, the MCPyV DNA
qPCR assay showed a dynamic range that spanned 7 orders
of magnitude. Thus, when averaging the values for all the
swabs for an individual, the standard deviation is relatively
small (less than one log) as shown in Fig. 1. This suggests
that, while viral loads may show occasional peaks or
troughs over time, individual subjects generally remain
within their quartile of MCPyV DNA load (negative, low,
medium, or high) over the course of several months.
The average standardized MCPyV load for all time
points for swabs taken from the dorsal surface of hands
correlated strongly with the MCPyV load found on the
forehead (Spearman’s rho of 0.842, P\0.0001) (Fig. 1).
Cohort A showed a similar positive monotonic correlation
between samples from the hand and forehead (Spearman’s
rho of 0.667, P = 0.005) (Supplemental Figure 1). For
cohort A, where three different skin sites were sampled, a
similar high degree of monotonic correlation was observed
for MCPyV DNA load on individuals’ hands versus
buttocks (Spearman rho = 0.768, P\0.001) or buttocks
versus forehead (Spearman rho = 0.627, P = 0.009)
(Supplemental Figure 1). The results show that, for a given
individual, the amount of shed MCPyV DNA is similar at
multiple anatomic sites.
Only three volunteers (6%) were negative for MCPyV
for all swabs at all time points in both cohorts. Sixteen
Fig. 1 Comparison of MCPyV DNA load at two anatomical sites for
the 33 subjects in cohort B. Each data point reﬂect the average
MCPyV DNA load (expressed as copies of MCPyV DNA per copy of
human beta-globin DNA) observed in skin swab specimens taken
from the dorsum of the hand (x-axis) or the forehead (y-axis) at four
time points. Error bars depict one standard deviation. Two samples
overlap at coordinates x = 0.001, y = 0.001
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anatomical sites tested (in cohort A, 1 volunteer was only
sampled once). Within the uniformly positive group,
MCPyV could be detected at a 4-fold excess over beta-
globin in at least one swab. The highest level of MCPyV
detected was in a volunteer who had more than 1,000
copies of MCPyV per copy of beta-globin in two consec-
utive hand swabs and one forehead swab (subject ID B8,
Supplemental Table 1). There was no apparent correlation
between the age of the volunteers and the MCPyV DNA
load (Supplemental Figure 2). Also, there were no evident
differences between men and women in MCPyV DNA load
(Supplemental Table 1).
MCPyV-speciﬁc antibody responses
We used a previously reported serological assay that
measures MCPyV capsid-speciﬁc antibodies capable of
neutralizing the infectivity of an MCPyV-based reporter
vector (pseudovirus). The majority (80%) of volunteers had
detectable MCPyV capsid-speciﬁc antibody responses. The
geometric mean 50% neutralizing serum dilution (EC50)
for all subjects in the study was 3,800. The results are
consistent with previous studies of healthy adult popula-
tions [3]. A subset of 31 volunteers contributed two serum
samples 11–15 months apart. In most instances, the neu-
tralizing EC50 values for the two time points differed by
less than two-fold (Fig. 2 and Supplemental Figure 4).
There was only a marginal correlation between the age of
the volunteers and MCPyV-speciﬁc serum neutralizing titer
(Spearman’s rho of 0.3101, P = 0.0301); however, the
correlation might not be apparent because the sample
population was biased toward the 3rd and 4th decades of
life (60% of volunteers are in this category). There were no
apparent differences between men and women in MCPyV
serum titers (Supplemental Table 1).
Correlation between MCPyV DNA load and MCPyV-
speciﬁc antibody response
In this part of the study, we aimed to examine whether
there was a correlation between an individual subject’s
anti-MCPyV antibody titer and their MCPyV viral load.
Comparison of individual subjects’ overall viral load
(average of all time points for all anatomical sites) to their
average serological titer revealed a strong positive mono-
tonic correlation (Spearman rho 0.644, P\0.0001)
(Fig. 3). Although there was a strong positive monotonic
correlation between MCPyV load and MCPyV-neutralizing
antibody responses for the population as a whole, there was
one person with a neutralizing titer of about 7,000 but no
detectable virus in any swab (ID B20, Supplemental
Table 1). Conversely, a set of four individuals (ID = A1,
B3, B21, B24, Supplemental Table 1) displayed low or
undetectable serological responses despite rather high
mean MCPyV DNA loads (2–46 copies per copy of beta-
globin). In three (ID = B3, B21, B24) of the four indi-
viduals, these average loads were due to high values in
single swabs, and the moderate average loads for the
remaining swabs were 3.3, 0.001, and 0.2 versus 46.0, 4.3,
and 5.1, respectively.
Beta-globin was used to normalize the MCPyV DNA
loads, as the closest available proxy for how many epithelial
cells were captured in the swab specimen. However, the
virus could also be extracellular or associated with squa-
mous cells devoid of DNA [15], and thus viral load less
dependent on the number of intact epithelial cells in the
swab. To address this aspect, we compared the unstan-
dardized MCPyV DNA load to MCPyV-neutralizing titers.
This data also showed a positive monotonic correlation
(Spearman rho 0.696, P\0.0001) that was very similar to
the beta-globin normalized data (Supplemental Figure 3).
Discussion
The data presented in this report support two general
conclusions. The ﬁrst conclusion is that nearly all healthy
Fig. 2 Stability of MCPyV-speciﬁc antibody titers. Sera were
obtained from 31 volunteers at two time points 11–15 months apart.
Samples were serially diluted and used in a MCPyV reporter vector-
based neutralizing assay. The plot shows the 50% neutralizing titer
(EC50) for each subject’s initial (x-axis) versus repeat (y-axis) serum
sample. Error bars depict the 95% conﬁdence interval. Four samples
overlap at coordinates x = 100, y = 100; two samples overlap at
coordinates x = 178 (184), y = 100; and two samples overlap at
coordinates x = 3,098 (3,182), y = 11,935 (11,600)
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123individuals chronically shed MCPyV DNA, likely in the
form of virions [15], from the surface of their skin. A
second conclusion is that the amount of MCPyV DNA that
is chronically shed from the skin is typically reﬂected in the
magnitude of a subject’s serum antibody responsiveness to
the MCPyV capsid. This is consistent with the concept that
the skin is a primary reservoir of productive MCPyV
infection, although it does not exclude the possibility that
there might be additional sites of MCPyV infection.
In this study, individual subjects were found to shed
similar amounts of MCPyV DNA from their hands, fore-
heads, and buttocks, suggesting that MCPyV infection is
typically widespread over various skin surfaces. The hands
and face typically come into contact several times per hour
[28], which could increase the degree of correlation in the
surface MCPyV load for these sites. However, strong
correlations were also observed between the MCPyV loads
on each individual’s forehead and buttocks, as well as on
their hands and buttocks. Thus, the results indicate that the
magnitude of a given individual’s MCPyV burden is gen-
erally uniform across a range of environmentally exposed
and unexposed skin areas. The mechanism through which
productive MCPyV infections apparently persist despite
robust anti-MCPyV antibody responses is unknown.
The lower limit of detection for the MCPyV neutral-
ization assay has been previously discussed [3]. The limit
was set at a serum dilution of 1:100 because that was the
lowest dilution at which serum from unimmunized rabbits
was less than 50% neutralizing. We consider this to be a
conservative standard, particularly in light of the more
recent concept that putatively naı ¨ve laboratory rabbits
might be environmentally exposed to MCPyV virions shed
from the skin of their human handlers. It is likewise con-
ceivable that low-level neutralizing antibody titers in
humans could reﬂect environmental exposure to MCPyV,
as opposed to actual infection. In this manuscript, for
graphing purposes, all volunteers that did not reach an
EC50 at a dilution of 1:100 were assigned a titer of 100.
However, the actual MCPyV-speciﬁc titers of these
subjects could theoretically be much lower, or even
non-existent. These limitations restrict the power of the
correlation between serum titer and viral load at the lower
end of the spectrum. Consistent with this idea, the corre-
lation between viral load and antibody titer was substan-
tially stronger at the high end of the spectrum.
There were a few speciﬁc exceptions to the correlation
between viral load and antibody titers. Study volunteer B20
showed no detectable virus in all eight of the skin swab
specimens but nevertheless showed a relatively high sero-
logical titer (1:6,700). It is conceivable that this person
developed an immune response that resulted in clearance of
the MCPyV infection. Another possible explanation would
be that the subject carries an MCPyV infection that is
localized to skin, mucosal surfaces, or other anatomical
sites that were not sampled in the current study. Four
individuals with moderate viral loads displayed either
undetectable or very low levels of anti-MCPyV antibodies.
This may indicate that some individuals are not able to
mount (or have simply not yet mounted) a humoral
immune response, despite ongoing or episodic MCPyV
infection. To begin to examine the concept that antibody
responses associated with moderate levels of MCPyV
shedding are very slow to develop, we stratiﬁed volunteers
for whom two serological time points were available into
quartiles according to their viral load. Subjects in the
bottom three quartiles of viral load seemed to show a
general trend toward increasing antibody titers over the
11–15 months sampling interval (Supplemental Figure 4).
In contrast, subjects in the top quartile of viral load
appeared to show slightly decreasing titers. The concept
that MCPyV-speciﬁc antibody responses may be mounted
over the course of many years could partially explain the
relatively weaker correlation between antibody titer and
MCPyV viral load for individuals in the middle and lower
end of the spectrum. Obtaining a clearer answer to the
question of the kinetics of the induction of B cell responses
against the MCPyV will likely require analysis of serum
samples collected over much longer time periods.
High titer MCPyV capsid-speciﬁc antibody responses
can be found in both the normal human population and in
Fig. 3 Correlation between viral load and anti-MCPyV-neutralizing
titer. For each of the 49 volunteers, the normalized MCPyV DNA
load was averaged for all the anatomical sites (foreheads, hands and,
when available, buttocks) at all time points (1–10 time points
spanning 0 months to 4 years). For the neutralizing titer, the average
EC50 from two serum collections was plotted, when available. Two
samples overlap at coordinates x = 0.001, y = 100
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MCPyV-neutralizing titer of individuals with MCC is
about 60-fold higher compared to healthy controls. In
light of the data reported in the current study, it seems
likely that the unusually high MCPyV-speciﬁc serological
titers in MCC patients reﬂect a history of unusually high
MCPyV viral load in these subjects’ skin. An implication
of this model could be that poorly controlled MCPyV
infection might be one of the risk factors for development
of MCC.
It is not yet clear whether MCPyV is associated with
additional human diseases beyond MCC. Other potential
MCPyV-associated disease states might, like MCC, be
associated with unusually high levels of MCPyV DNA on
the surface of the skin and/or unusually strong MCPyV-
speciﬁc seroresponses.
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